CCM
JAZZ icon

Chilton Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Chilton Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$723 – 651
2024
Q1 		$723 Hold
6
– – ﹤0.01% 576
2023
Q4 		$738 Buy
+6
New +$749 ﹤0.01% 578

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Chilton Capital Management's JAZZ Position: Q2 2024 in Review

Chilton Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 6 shares — an estimated $723 sold.

Chilton Capital Management first reported a position in JAZZ in Q4 2023 and held it in 2 quarters. The position peaked at $738 in Q4 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Chilton Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Chilton Capital Management sold 6 Jazz Pharmaceuticals shares in Q2 2024, an estimated $723.
  • Chilton Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Chilton Capital Management's Jazz Pharmaceuticals position peaked at $738 in Q4 2023.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Chilton Capital Management's 13F filing for Q2 2024, filed 1 Aug 2024.